Anavex Life Sciences Corp (AVXL)

[crescentmotor]

All the SAVA claims presently rest on unblinded data.

Not true as part of the Phase II was a randomized placebo controlled six month drug withdrawal trial. In patients with mild Alzheimer's, the largest separation between the continuous and non-continuous treatment groups occurred at the end of the 6-month randomized, placebo-controlled withdrawal phase after which all patients resumed treatment with Simufilam. SAVA has reported no cognitive loss in patients with mild Alzheimer's Disease in patients treated continuously with Simufilam for twenty-four months. Unblinded data starts telling a story once a placebo group gets out to eighteen months or longer because of well established placebo effect over that timeframe. I guarantee you AVXL is anxious to see the results of its unblinded open label extension trial that will provide data beyond twelve months. AVXL may even be holding up talking to the FDA about a regulatory path forward until that OLE data is available.